资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

Clin. Infect. Dis.. 2019-08;

StevensElizabeth R，NuciforaKimberly A，HaganHolly，JordanAshly E，UyeiJennifer，KhanBilal，DombrowskiKirk，des JarlaisDon，BraithwaiteR S

Products/Services Used	Details	Operation
Peptide Synthesis	… In brief, 8-10 weeks old female mice were immunized at base of tail and both thighs with 200 μg of mouse MOG 79-96 peptide (custom synthesized by Genscript, NJ) emulsified in Complete Freund's Adjuvant (CFA) (Sigma, MO) that had been supplemented with M. tuberculosis …	Get A Quote

摘要

There are too many plausible permutations and scale-up scenarios of combination hepatitis C (HCV) interventions for exhaustive testing in experimental trials. Therefore， we used computer simulation to project the health and economic impact of alternative combination intervention scenarios for people who inject drugs (PWID)， focusing on direct anti-viral agents (DAA) and medication-assisted treatment combined with syringe access programs (MAT+).